B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models

Journal of Immunotherapy

Volumn 31, Issue 5, 2008, Pages 446-457

  Kim, Samuel ^a   Fridlender, Zvi G ^a   Dunn, Robert ^b   Kehry, Marilyn R ^b   Kapoor, Veena ^a   Blouin, Aaron ^a   Kaiser, Larry R ^a   Albelda, Steven M ^a,c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b BIOGEN   (United States)

^c Penn Hand Center   (United States)

Author keywords

Antibody therapy; B cells; Immunosuppression; Lung cancer; Mesothelioma; Tumor immunology

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CD20 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 18B12; PROTEIN E7; RITUXIMAB; UNCLASSIFIED DRUG; CANCER VACCINE; CD20 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; DRUG EFFICACY; LUNG CANCER; LYMPHOCYTE DEPLETION; MESOTHELIOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYMOMA; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REGRESSION; ADENOVIRUS; ANIMAL; CELL LINE; DISEASE COURSE; DISEASE MODEL; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; KINETICS; LYMPHOCYTE ACTIVATION; NEOPLASM; PATHOLOGY; SPLEEN;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENETIC VECTORS; IMMUNOTHERAPY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KINETICS; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS; SPLEEN;

EID: 55249103660     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31816d1d6a     Document Type: Article

References (46)

1. Houghton AN, Uchi H, Wolchok JD. The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword. Cancer Cell. 2005;7:403-405.
2. Harada M, Okamoto T, Kurosawa S, et al. The antitumor activity induced by the in vivo administration of activated B cells bound to anti-cd3 monoclonal antibody. Cell Immunol. 1995;161:132-137.
3. Donepudi M, Jovasevic VM, Raychaudhuri P, et al. Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells. Cancer Immunol Immunother. 2003;52:162-170.
4. Maecker B, von Bergwelt-Baildon MS, Sherr DH, et al. Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1. Int J Cancer. 2005;115:333-336.
5. O'Brien P, Millan DWM, Davis J, et al. In situ isolation of immunoglobulin sequences expressed by single tumor-infiltrating B cells using laser-assisted microdissection. Mol Biotechnol. 2004; 26:39-60.
6. Kemp TJ, Moore JM, Griffith TS. Human B cells express functional TRAIL/apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation. J Immunol. 2004;173:892-899.
7. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol. 2007;19:209-216.
8. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell. 2005;7:411-423.
9. Schilbach K, Kreyenberg H, Geiselhart A, et al. Cloning of a human antibody directed against human neuroblastoma cells and specific for human translation elongation factor 1-alpha. Tissue Antigens. 2004;63:122-131.
10. Kawakami K, Terabe M, Kawakami M, et al. Characterization of a novel human tumor antigen interleukin-13 receptor chain alpha-2 chain. Cancer Res. 2006;68:4434-4442.
11. Qin Z, Richter G, Schuler T, et al. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med. 1998;4:627-630.
12. Shah S, Divekar AA, Hilchey SP, et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer. 2005;117: 574-586.
13. Brodt P, Gordon J. Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. J Immunol. 1978; 121:359-362.
14. + and B lymphocytes in transplanation immunity: augmented rejection of tumor allografts by mice lacking B cells. Transplantation. 1993;55:1356-1361.
15. Inoue S, Leitner WW, Golding B, et al. Inhibitory effects of B cells on antitumor immunity. Cancer Res. 2006;66:7741-7777.
16. Chapoval AI, Fuller JA, Kremlev SG, et al. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J Immunol. 1998;161:6977-6984.
17. Perricone MA, Smith KA, Claussen KA, et al. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother (1997). 2004;27:273-281.
18. Watt V, Ronchese F, Ritchie D. Resting B cells suppress tumor immunity via an MHC class-II dependent mechanism. J Immunother (1997). 2007;30:323-332.
19. Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Ann Rev Med. 2004;55:477-503.
20. Ahuja A, Shupe J, Dunn R, et al. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol. 2007;179:3351-3361.
21. Davis MR, Manning LS, Whitaker D, et al. Establishment of a murine model of malignant mesothelioma. Int J Cancer. 1992;52: 881-886.
22. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigens. Cancer Res. 1996;56:21-26.
23. Wilderman M, Sun J, Khan M, et al. Intrapulmonary interferon-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of lung adenocarcinoma via a combination of direct toxicity, NK cell, and CD8 T-cell mediated effects. Cancer Res. 2005;65:8379-8387.
24. O'Keefe TL, Williams GT, Davies SL, et al. Mice carrying a CD20 gene disruption. Immunogenetics. 1998;48:125-132.
25. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-497.
26. Haas A, Sun J, Vachani A, et al. Cyclooxygenase-2 inhibition augments efficacy of a cancer vaccine. Clin Cancer Res. 2006; 12:214-222.
27. Sterman DH, Recio A, Vachani A, et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high dose adenovirus herpes simplex thymidine kinase (HSVtk)/ganciclovir (GCV) suicide gene therapy. Clin Cancer Res. 2005;11: 7444-7453.
28. North RJ. Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells. J Exp Med. 1986;164: 1652-1666.
29. Suzuki E, Kapoor V, Cheung HK, et al. Soluble type II transforming growth factor-β receptor inhibits both small and large established murine malignant mesothelioma tumor growth by augmenting host anti-tumor immunity. Clin Cancer Res. 2004;10: 5907-5918.
30. Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203:2691-2702.
31. Quezada SA, Peggs KS, Curran MA, et al. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006;116: 1935-1945.
32. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199:1659-1669.
33. Uchida J, Lee Y, Hasegawa M, et al. Mouse CD20 expression and function. Int Immunol. 2004;16:119-129.
34. Kruklitis RJ, Singhal S, Delong P, et al. Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J Thorac Cardiovasc Surg. 2004;127:123-130.
35. Barbera-Guillem E, Nelson MB, Barr B, et al. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother. 2000;48:541-549.
36. Fuchs EJ, Matzinger P. B cells turn off virgin but not memory T cells. Science. 1992;258:1156-1159.
37. Eynon EE, Parker DC. Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med. 1992;175:131-138.
38. Bennett SR, Carbone FR, Toy T, et al. B cells directly tolerize CD8(+) T cells. J Exp Med. 1998;188:1977-1983.
39. Moulin V, Andris F, Thielemans K, et al. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med. 2000;192:475-482.
40. Wijesuriya R, Maruo S, Zou JP, et al. B cell-mediated down-regulation of IFN-gamma and IL-12 production induced during anti-tumor immune responses in the tumor-bearing state. Int Immunol. 1998;10:1057-1065.
41. Maruo S, Oh-hora M, Ahn HJ, et al. B cells regulate CD40 ligand-induced IL-12 production in antigen-presenting cells (APC) during T cell/APC interactions. J Immunol. 1997;158:120-126.
42. - APC in mouse spleen. J Immunol. 2004;173: 2362-2372.
43. Rowley DA, Stach RM. B lymphocytes secreting IgG linked to latent transforming growth factor-beta prevent primary cytolytic T lymphocyte responses. Int Immunol. 1998;10:355-363.
44. Parekh VV, Prasad DV, Banerjee PP, et al. B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: role of TGF-beta 1. J Immunol. 2003;170:5897-5911.
45. Aklilu M, Stadler WM, Markiewicz M, et al. Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol. 2004;15:1109-1114.
46. Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res. 2007;13:3776-3782.